Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial
As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.
Stocks · News reference
Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027
The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police,
Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027Up to 200 participants at sites across Canada, among the largest studies